stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Book value per share
Vericel Corporation's book value per share at the end of fiscal 2025 was 7.0×, up 17.9% from 6.0× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 7.5×. Over the past ten years it has ranged from 0.7× (fiscal 2017) to 7.0× (fiscal 2025) — the current reading is the highest in ten years. Vericel Corporation ranks 105th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 7.0× | 17.86% |
| FY2024 | 6.0× | 25.89% |
| FY2023 | 4.7× | 16.38% |
| FY2022 | 4.1× | 11.22% |
| FY2021 | 3.7× | 23.55% |
| FY2020 | 3.0× | 18.08% |
| FY2019 | 2.5× | (1.02%) |
| FY2018 | 2.5× | 275.91% |
| FY2017 | 0.7× | (36.84%) |
| FY2016 | 1.1× | 14.87% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 7.5× | 3.59% |
| Jun 2026 | 7.2× | 3.26% |
| Mar 2026 | 7.0× | (0.41%) |
| Dec 2025 | 7.0× | 10.51% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 9.2× |
| VCEL Vericel Corporation | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| PHVS Pharvaris N.V. compare | 5.1× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| IMNM Immunome, Inc. compare | 4.6× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement